Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/regulation-and-welfare-evidence-from-paragraph-iv-generic-entry-in-the-XW0mCHMbuW
References (146)
-
Aviv Nevo (2001)
Measuring Market Power in the Ready-to-Eat Cereal IndustryPublic Economics
-
(2007)
TRANDOLAPRIL (3) Mavik Apr-96 Apr-01 Jun-07 Apr-15 Q1 -
M. Rosenthal, E. Berndt, J. Donohue, A. Epstein, R. Frank (2003)
Frontiers in Health Policy Research -
(2009)
Authorized Generics: An Interim Report. FTC study -
Alpert (2013)
Perverse Reserve Price Competition: Average Wholesale Prices and Medicaid Pharmaceutical SpendingJournal of Public Economics, 108
-
Abe Dunn (2013)
Drug Innovations and Welfare Measures Computed from Market Demand: The Case of Anti-Cholesterol Drugs -
Amil Petrin (2001)
Quantifying the Benefits of New Products: The Case of the MinivanJournal of Political Economy, 110
-
(2007)
VERAPAMIL (2) Verelan PM Nov-98 Nov-03 Jun-07 Jun-07 Q3 -
C. Chatterjee, K. Kubo, V. Pingali (2015)
The Consumer Welfare Implications of Governmental Policies and Firm Strategy in Markets for Medicines, 44
-
Sofronis Clerides (2008)
Gains from Trade in Used Goods: Evidence from AutomobilesIO: Empirical Studies of Firms & Markets
-
Steven Berry, J. Levinsohn, A. Pakes (1998)
Differentiated Products Demand Systems from a Combination of Micro and Macro Data: The New Car MarketJournal of Political Economy, 112
-
Matthew Higgins, Stuart Graham (2009)
Balancing Innovation and Access: Patent Challenges Tip the ScalesScience, 326
-
Farasat Bokhari, G. Fournier (2013)
ENTRY IN THE ADHD DRUGS MARKET: WELFARE IMPACT OF GENERICS AND ME-TOO'S*The Journal of Industrial Economics, 61
-
H. Grabowski (2007)
Pharmaceutical Innovation: Incentives, Competition, and Cost?Benefit Analysis in International Perspective -
F. Scherer (2001)
The link between gross profitability and pharmaceutical R&D spending.Health affairs, 20 5
-
S. Ellison, I. Cockburn, Z. Griliches, J. Hausman (1997)
Characteristics of demand for pharmaceutical products: an examination of four cephalosporins.The Rand journal of economics, 28 3
-
Steven Berry, J. Levinsohn, A. Pakes (1995)
Automobile Prices in Market EquilibriumEconometrica, 63
-
H. Grabowski (2012)
Are the economics of pharmaceutical research and development changing?PharmacoEconomics, 22
-
T. Bresnahan, Scott Stern, M. Trajtenberg (1996)
Market Segmentation and the Sources of Rents from Innovation: Personal Computers in the Late 1980&Apos;SKauffman: Entrepreneurship Scholars Initiatives (Topic)
-
Z. Griliches, I. Cockburn (1993)
Generics and New Goods in Pharmaceutical Price IndexesERN: Other IO: Empirical Studies of Firms & Markets (Topic)
-
T. Bresnahan, P. Reiss (1991)
Entry and Competition in Concentrated MarketsJournal of Political Economy, 99
-
Instruments used: Form number, number of firms in quarter, time since generic entry and lags -
Abby Alpert, Mark Duggan, J. Hellerstein (2013)
Perverse Reverse Price Competition: Average Wholesale Prices and Medicaid Pharmaceutical SpendingERN: Government Expenditures & Health (Topic)
-
Heidi Williams (2013)
Intellectual Property Rights and Innovation: Evidence from the Human GenomeJournal of Political Economy, 121
-
A. Dick (2002)
Demand Estimation and Consumer Welfare in the Banking IndustryBoard of Governors: Finance & Economics Discussion Series (Topic)
-
N. Cardell (1997)
Variance Components Structures for the Extreme-Value and Logistic Distributions with Application to Models of HeterogeneityEconometric Theory, 13
-
Charles Moul (2006)
Consequences of omitting advertising in demand estimation: An application to theatrical movies -
(2004)
Plendil Jul-91 Jul-96 Dec-01 Oct-07 Q4 -
J. DiMasi, R. Hansen, H. Grabowski (2003)
The price of innovation: new estimates of drug development costs.Journal of health economics, 22 2
-
E. Berndt, J. Newhouse (2010)
Pricing and Reimbursement in U.S. Pharmaceutical MarketsHealth Economics eJournal
-
(2009)
Federal Trade Commission Authorized Generic Drugs: An Interim Report -
H. Grabowski (2007)
Data Exclusivity for New Biological Entities -
(2011)
FRANK, R -
(2004)
Lopressor HCT Dec-84 Dec-89 Apr-92 Dec-93 Q3 -
Steven Berry, J. Waldfogel (1996)
Free Entry and Social Inefficiency in Radio BroadcastingIndustrial Organization & Regulation eJournal
-
Kevin Murphy, R. Topel (2003)
Measuring the Gains from Medical Research: An Economic Approach -
P. Danzon, Li-Wei Chao (2000)
Cross-national price differences for pharmaceuticals: how large, and why?Journal of health economics, 19 2
-
THE CONGRESS OF THE UNITED STATES.Science, 23 577
-
Pengxiang Li, S. McElligott, H. Bergquist, J. Schwartz, Jalpa Doshi (2012)
Effect of the Medicare Part D Coverage Gap on Medication Use Among Patients With Hypertension and HyperlipidemiaAnnals of Internal Medicine, 156
-
Aviv Nevo (2000)
Mergers with differentiated products: the case of the ready-to-eat cereal industryThe RAND Journal of Economics, 31
-
(2005)
Patents, Price Controls, and Access to New Drugs: How Policy Affects Global Market Entry -
K. Train (2003)
Discrete Choice Methods with Simulation -
V. Suslow (1992)
Are there better ways to spell relief? : a hedonic pricing analysis of ulcer drugs -
H. Grabowski, M. Kyle (2007)
Generic competition and market exclusivity periods in pharmaceuticalsManagerial and Decision Economics, 28
-
F. Lichtenberg (2003)
The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982–2001International Journal of Health Care Finance and Economics, 5
-
H. Grabowski, J. Vernon (1997)
Longer Patents for Increased Generic Competition: The Waxman-Hatch Act after One Decade -
J. Bulow (2004)
Innovation, Policy and the Economy, 4
-
Fiona Morton (2000)
Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industryInternational Journal of Industrial Organization, 18
-
L. Branstetter, C. Chatterjee, M.J. Higgins (2011)
Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical industry -
F. Lichtenberg (1998)
Pharmaceutical Innovation, Mortality Reduction, and Economic GrowthHealth Economics
-
Angiotensins and their combinations with calcium antagonists or diuretics (C9C0+C9D1+C9D3) have not faced patent expiration or Para-IV challenges and were thus excluded from the sample -
K. Lancaster (1966)
A New Approach to Consumer TheoryJournal of Political Economy, 74
-
D. McFadden (1972)
Conditional logit analysis of qualitative choice behavior -
(2010)
Pharmaceutical firm response to Paragraph-IV challenges: The role of complementary assets and non-novel therapeutics -
P. Ellickson, S. Stern, M. Trajtenberg (2001)
Medical Care Output and Productivity -
M. Rosenthal, E. Berndt, J. Donohue, A. Epstein, R. Frank (2003)
Demand Effects of Recent Changes in Prescription Drug PromotionForum for Health Economics & Policy, 6
-
E. Brynjolfsson, Yu Hu, Michael Smith (2003)
Consumer Surplus in the Digital Economy: Estimating the Value of Increased Product Variety at Online BooksellersMIT Sloan School of Management Working Paper Series
-
L. Dafny, M. Duggan, S. Ramanarayan (2012)
Premium on Your Premium? Consolidation in the Health Insurance Industry, 102
-
Atanu Saha, H. Grabowski, H. Birnbaum, P. Greenberg, O. Bizan (2006)
Generic Competition in the US Pharmaceutical IndustryInternational Journal of the Economics of Business, 13
-
(2013)
Does Pharma Spend More on Marketing than R&D? A Numbers Check FiercePharma, http://www.fiercepharma.com/story/does-pharma-spend-more-marketing-rd-numbers-check -
(2001)
FosinoprilReactions Weekly, 850
-
E. Berndt, Richard Mortimer, A. Bhattacharjya, A. Parece, E. Tuttle (2007)
Authorized generic drugs, price competition, and consumers' welfare.Health affairs, 26 3
-
Y. Zhang, J. Lave, J. Donohue, M. Fischer, M. Chernew, J. Newhouse (2010)
The Impact of Medicare Part D on Medication Adherence Among Older Adults Enrolled in Medicare-Advantage ProductsMedical Care, 48
-
R. Frank, D. Salkever (1995)
Generic Entry and the Pricing of Pharmaceuticals -
(2009)
“ Time Release : The Effect of Patent Expiration on U . S . Drug Prices , Marketing , and Utilization By the Public -
(2007)
Pharmaceutical Price Controls and Entry Strategies -
D. Ironmonger, K. Lancaster (1972)
Consumer Demand. A New Approach.Economica, 42
-
Darius Lakdawalla, T. Philipson, Y. Wang (2006)
WORKING PAPER SERIES INTELLECTUAL PROPERTY AND MARKETING -
Berry (1995)
Automobile Prices in EquilibriumEconometrica, 63
-
E. Berndt (2002)
Pharmaceuticals in U.S. health care: determinants of quantity and price.The journal of economic perspectives : a journal of the American Economic Association, 16 4
-
D. Reiffen, Michael Ward (2002)
Generic Drug Industry DynamicsReview of Economics and Statistics, 87
-
E. Berndt, R. Pindyck, Pierre Azoulay (2000)
Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer DrugsIO: Empirical Studies of Firms & Markets
-
(2004)
Entry, Pricing, and Product Design in an Initially Monopolized Market -
C. Leake (1995)
Discrete Choice Theory of Product DifferentiationJournal of the Operational Research Society, 46
-
Appelt (2015)
Authorized Generic Entry Prior to Patent Expiry: Reassessing Incentives for Independent Generic EntryReview of Economics and Statistics, 97
-
E. Berndt, Anupa Bir, S. Busch, R. Frank, S. Normand (2000)
The Medical Treatment of Depression, 1991-1996: Productive Inefficiency, Expected Outcome Variations, and Price IndexesHealth Economics
-
M. Trajtenberg (1989)
The Welfare Analysis of Product Innovations, with an Application to Computed Tomography ScannersJournal of Political Economy, 97
-
J. Wooldridge (1999)
Distribution-free estimation of some nonlinear panel data modelsJournal of Econometrics, 90
-
E. Berndt, L. Bui, D. Reiley, G. Urban (1995)
Information, marketing, and pricing in the U.S. antiulcer drug market.The American economic review, 85 2
-
Fiona Morton, Fiona Morton (1999)
Entry decisions in the generic pharmaceutical industry.The Rand journal of economics, 30 3
-
Paris Cleanthous (2002)
Patient Welfare Implications of Innovation in the U.S. Antidepressant Market 1 -
J. Ferrándiz (1999)
The impact of generic goods in the pharmaceutical industry.Health economics, 8 7
-
Jeremy Bulow (2003)
The Gaming of Pharmaceutical PatentsInnovation Policy and the Economy, 4
-
S. Knowles (2010)
Fixing the Legal Framework for Pharmaceutical ResearchScience, 327
-
Christian Broda, David Weinstein (2004)
Globalization and the Gains from Variety -
Leemore Dafny, M. Duggan, S. Ramanarayanan (2009)
Paying a Premium on Your Premium? Consolidation in the U.S. Health Insurance IndustryLabor: Personnel Economics eJournal
-
F. Lichtenberg (1996)
Do (more and better) drugs keep people out of hospitals?The American economic review, 86 2
-
Murray Aitken, E. Berndt, D. Cutler (2008)
Prescription drug spending trends in the United States: looking beyond the turning point.Health affairs, 28 1
-
I. Cockburn (2006)
Is the Pharmaceutical Industry in a Productivity Crisis?Innovation Policy and the Economy, 7
-
F. Sloan, C. Hsieh (2007)
Pharmaceutical Innovation: List of Figures -
E. Berndt, I. Cockburn, Z. Griliches (1996)
Pharmaceutical Innovations and Market Dynamics: Tracking Effects on Price Indexes for Antidepressant Drugs, 27
-
Antara Dutta (2011)
From Free Entry to Patent Protection: Welfare Implications for the Indian Pharmaceutical IndustryThe Review of Economics and Statistics, 93
-
L. Panattoni (2011)
The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.Journal of health economics, 30 1
-
D. Acemoglu, Joshua Linn (2003)
Market Size in Innovation: Theory and Evidence from the Pharmaceutical IndustryMIT Economics Department Working Paper Series
-
W. Nordhaus (2002)
The Health of Nations: The Contribution of Improved Health to Living StandardsNBER Working Paper Series
-
Steven Berry (1994)
Estimating Discrete-Choice Models of Product DifferentiationThe RAND Journal of Economics, 25
-
(2005)
Do Formal Intellectual Property Rights Hinder the Free Flow of Scientific Knowledge? An Empirical Test of the Anti-Commons Hypothesis -
(2005)
The Regulation of Entry. -
Stage (Price)=12.62; F-First Stage (ln(adver)) -
R. Town, Su Liu (2003)
The welfare impact of Medicare HMOs.The Rand journal of economics, 34 4
-
Aviv Nevo, Jeffrey Dubin, Daniel McFadden, T. Bresnahan, Steven Berry (1999)
Measuring Market Power in the Ready-to-Eat Cereal Industry -
R. Caves, M. Whinston, M. Hurwitz (1991)
Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry, 22
-
Dependent Variable: Diff = ln(sjm)-ln(s0) -
Paul Ellickson, Scott Stern, M. Trajtenberg (1999)
Patient Welfare and Patient Compliance -- An Empirical Framework for Measuring the Benefits from Pharmaceutical InnovationNational Bureau of Economic Research
-
P. Danzon, Y. Wang, L. Wang (2005)
The Impact of Price Regulation on the Launch of Delay of New Drugs, 14
-
H. Rosen, K. Small (1979)
Applied Welfare Economics with Discrete Choice Models -
(1995)
Product differentiation and oligopoly in international markets: the case of the automobile industry -
Panattoni (2011) collected data from District Court decisions. 16 See http://www.cdc.gov/nchs/data/databriefs/db03.pdf. 17 The ATCs used to define the market are -
J. Donohue, M. Cevasco, M. Rosenthal (2007)
A decade of direct-to-consumer advertising of prescription drugs.The New England journal of medicine, 357 7
-
James Hughes, Michael Moore, Edward Snyder (2002)
"Napsterizing" Pharmaceuticals: Access, Innovation, and Consumer WelfareHealth Care Law & Policy eJournal
-
C. Hemphill, B. Sampat (2011)
When Do Generics Challenge Drug Patents?Health Economics eJournal
-
H. Grabowski, J. Vernon (1992)
Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug ActThe Journal of Law and Economics, 35
-
D. McFadden (1973)
Frontiers of Econometrics -
M. Hurwitz, R. Caves (1988)
Persuasion or Information? Promotion and the Shares of Brand Name and Generic PharmaceuticalsThe Journal of Law and Economics, 31
-
Chi-sq(1) P-val 0 -
P. Huckfeldt, Christopher Knittel (2011)
Pharmaceutical Use Following Generic Entry: Paying Less and Buying LessEconometrics: Applied Econometrics & Modeling eJournal
-
C. Freeman, W. Nordhaus (1969)
Invention, Growth, and Welfare: A Theoretical Treatment of Technological Change by William D. Nordhaus (review)Technology and Culture, 12
-
F. Lichtenberg (2001)
Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS.Health affairs, 20 5
-
J. Hausman, Bronwyn Hall, Z. Griliches (1984)
Econometric Models for Count Data with an Application to the Patents-R&D RelationshipERN: Econometric Modeling in Microeconomics (Topic)
-
Jay Bhattacharya, William Vogt (2003)
A Simple Model of Pharmaceutical Price Dynamics*The Journal of Law and Economics, 46
-
Generic Entry Prior to Patent Expiration -
Berndt (2003)
Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer DrugsJournal of Industrial Economics, 51
-
Hansen J Statistic -
H. Grabowski (2007)
Competition between Generic and Branded Drugs -
H. Grabowski, J. Vernon (2012)
Longer Patents for Increased Generic Competition in the USPharmacoEconomics, 10
-
P. Danzon, Li-Wei Chao (2000)
Does Regulation Drive Out Competition in Pharmaceutical Markets?*The Journal of Law and Economics, 43
-
P. Danzon, Y. Wang, Liang Wang (2003)
The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-Five Major Markets in the 1990sHealth Economics eJournal
-
M. Gj (1999)
Overview of the Hatch-Waxman Act and its impact on the drug development process.Food and Drug Law Journal, 54
-
T. Bresnahan, R. Gordon (1997)
The Economics of New Goods -
(1996)
Does Pharma Spend More on Marketing Than R & D ? A Numbers Check Market Definition and Returns to Innovation : Substitution Patterns in Pharmaceutical Markets -
K. Train (2003)
Discrete Choice Methods with Simulation by Kenneth E. Train -
C. Hemphill, B. Sampat (2011)
Evergreening, Patent Challenges, and Effective Market Life in PharmaceuticalsIntellectual Property: Patent Law eJournal
-
E. Berndt, Murray Aitken (2010)
Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch LegislationInternational Journal of the Economics of Business, 18
-
Aviv Nevo (2000)
A Practitioner's Guide to Estimation of Random‐Coefficients Logit Models of DemandERN: Other Microeconomics: Decision-Making under Risk & Uncertainty (Topic)
-
J. DiMasi, H. Grabowski (2007)
The cost of biopharmaceutical R&D: is biotech different?Managerial and Decision Economics, 28
-
R. Henderson, I. Cockburn (1996)
Scale, scope, and spillovers: the determinants of research productivity in drug discovery.The Rand journal of economics, 27 1
-
J. Hudson (2000)
Generic take-up in the pharmaceutical market following patent expiry A multi-country studyInternational Review of Law and Economics, 20
-
(2004)
Accuretic Dec-99 Dec-04 Oct-00 Aug-07 Q2 -
(2001)
Pharmaceutical industry profile 2001: research for the millennium -
F. Fitzgerald, D. Kessler (2003)
Demand Effects of Recent Changes in Prescription Drug Promotion -
John Peterson, L. Bilheimer, J. Wagner, P. Gordon (1998)
HOW INCREASED COMPETITION FROM GENERIC DRUGS HAS AFFECTED PRICES AND RETURNS IN THE PHARMACEUTICAL INDUSTRY -
F. Lichtenberg (1996)
The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and MortalityHealth Economics Evaluation Methods eJournal
-
(2001)
Do Stronger Patents Induce More Innovation? Evidence from the 1988 Japanese Patent Law Reforms -
Prozac (2 mg/ 5 ml solution) Prozac (non solution formulations) Citalopram -
(2007)
CARVEDILOL (1) Coreg Sep-95 Sep-00 Sep-07 Aug-16 Q3 -
A. Gallant, Han Hong, Ahmed Khwaja (2008)
Estimating a Dynamic Oligopolistic Game with Serially Correlated Unobserved Production Costs∗
- Publisher
- Wiley
- Copyright
- © 2016 The RAND Corporation
- ISSN
- 0741-6261
- eISSN
- 1756-2171
- DOI
- 10.1111/1756-2171.12157
- Publisher site
- See Article on Publisher Site
Abstract
This article estimates welfare effects of accelerated generic entry via Paragraph IV challenges. Using data from 2000–2008 for hypertension drugs in the United States, we estimate demand using a random‐coefficients logit model. We find consumers gain $42 billion whereas producers lose $32.5 billion from entry. This modest $9.5 billion gain in social welfare is consistent with our observation that overall consumption does not increase after entry—generic sales displace branded sales, shifting surplus downstream from producers to consumers, insurance companies, and retailers. We demonstrate significant cross‐molecular substitution and discuss challenges in determining what fraction of downstream surplus actually goes to consumers.
Journal
The Rand Journal of Economics – Wiley
Published: Nov 1, 2016